trial

Minocycline for Schizophrenia

NCTId NCT01809158
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 150 (actual)
Sponsored by Addis Ababa University
Primary completion 2016-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
150 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-04
Primary completion
2016-05
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Minocycline

Sponsors

Addis Ababa UniversityLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Abebaw Fekadu, MD, PhDPrincipal Investigator

Sites

1 total
Addis Ababa, Ethiopia

Facts & assertions

4 sourced
Enrollment
150
Phase
PHASE4
Primary Completion Date
2016-05
Status
COMPLETED
relationships
The graph out of here
drug
Minocycline
drug
lead_sponsor
Addis Ababa University
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Abebaw Fekadu, MD, PhD
person